We're rebuilding our media kit with real audience intelligence. Enter the preview password to see what's inside.
A Financial Times Publication
252,000+ verified subscribers. Classified by seniority, function, industry, and therapeutic specialty. The most precisely targeted audience in biotech media.
Most publishers can tell you their total audience size. We can tell you exactly how many VP-and-above R&D leaders at Big Pharma companies subscribe — and target your campaign to only them.
Every subscriber classified across seniority, job function, industry, and therapeutic specialty. No other biotech publication offers this depth.
Combine dimensions for laser-focused campaigns: "VP+ in Commercial at Big Pharma" or "Directors in R&D with Oncology focus."
All data from verified opt-in subscribers. Corporate email domain verification for industry classification. Privacy-first, aggregate reporting only.
A detailed look at who reads Endpoints News every day.
41% of our audience holds Director-level positions or above.
Professionals across every critical business function in biopharma.
Ready-to-activate audience segments combining seniority and function.
| Segment | Subscribers |
|---|---|
| R&D / Science — Directors & Above | 15,192 |
| Commercial / BD — Directors & Above | 14,261 |
| Clinical / Medical — Directors & Above | 10,756 |
| Marketing / Comms — Directors & Above | 6,435 |
| R&D / Science — VP & Above | 4,866 |
| Regulatory / Quality — Directors & Above | 4,840 |
| Data / Tech / AI — Directors & Above | 4,558 |
| Finance / Investment — VP & Above | 3,578 |
| Manufacturing / Supply — Directors & Above | 2,735 |
| Legal / IP — Directors & Above | 2,147 |
Reach professionals whose expertise is in a specific therapeutic area.
Verified through corporate email domain classification across 27,439 organizations.
Organization counts by corporate email domain. Individual subscriber counts within each industry are significantly higher.
Every product benefits from our audience intelligence targeting.
Reach a precisely defined audience segment with a dedicated email. Standard blasts reach our full list. Targeted blasts reach only your specified seniority, function, industry, and specialty combination.
Sponsor our daily or weekly newsletters. Your message appears alongside the industry news that 252,000+ professionals read every morning. Premium placement with verified audience reach.
Comprehensive multi-channel packages combining email, newsletter, web, and custom content. Maximum sustained visibility with the most engaged biopharma audience.
Reach 700,000+ monthly unique visitors on endpointsnews.com. Programmatic and direct-sold display inventory across our content pages.
Studio-produced content that tells your story to our audience. Written by experienced science journalists who understand biopharma. Distributed across email and web.
Tell us your target audience — we'll build a custom package that reaches exactly those people. Oncology C-Suite, Biotech R&D Leaders, Pharma Commercial VPs — you define it, we deliver it.
Real scenarios. Real targeting. Real results.
"We're launching an oncology drug and need to reach KOLs and prescribers."
"We want to announce our gene therapy approval to industry leaders."
"We're a CDMO looking for biotech clients who outsource manufacturing."
"We're a VC firm raising a biotech fund and need LP visibility."
"We're recruiting a Chief Medical Officer for a Series B biotech."
"We sell analytics software to pharma R&D teams."
"We're hosting an oncology-focused executive roundtable."
"We're rebranding after a merger and need industry awareness."
Tell us your target audience. We'll show you exactly how many of them read Endpoints — and how to reach them.
Custom audience profiles available during your first call.